Home Angiogenesis FGFR inhibitor Pemigatinib For research use only.

Pemigatinib

Synonyms: INCB054828

Pemigatinib is an orally active and selective inhibitor of FGFR with IC50 of 0.4 nM, 0.5 nM, 1.2 nM and 30 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma.

Pemigatinib Chemical Structure

Pemigatinib Chemical Structure

CAS No. 1513857-77-6

Purity & Quality Control

Pemigatinib Related Products

Signaling Pathway

FGFR Signaling Pathways

FGFR Signaling Pathway

Biological Activity

Description Pemigatinib is an orally active and selective inhibitor of FGFR with IC50 of 0.4 nM, 0.5 nM, 1.2 nM and 30 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma.
Targets
FGFR1 [1]
(Cell-free assay)		 FGFR2 [1]
(Cell-free assay)		 FGFR3 [1]
(Cell-free assay)		 FGFR4 [1]
(Cell-free assay)
0.4 nM 0.5 nM 1.2 nM 30 nM
In vitro
In vitro

Pemigatinib successfully diminishes the capacity of reactive astrocytes to recruit myeloid cells. Potentially FGFR modulation by pemigatinib may be promising for suppression of proinflammatory astrocyte responses while, at the same time, promoting protective mechanisms in murine and human systems.[2]
Cell Research Cell lines Primary mouse astrocytes
Concentrations 10 μM
Incubation Time 24 h
Method

Primary mouse astrocytes were stimulated with afatinib (10 μM), UNC2025 (10 μM), or pemigatinib (10 μM) for 24 hours. N2A neuronal cells were stimulated with ACM or control medium for 24 hours. Primary mouse astrocytes and N2A neuronal cells were detached and washed once in cold 1× PBS. Live/dead staining was performed. In addition, annexin V–propidium iodide staining was performed. Cells were washed once and resuspended in annexin V binding buffer before acquisition on a 3L Cytek Northern Lights flow cytometer. Analysis of flow cytometry data was performed with the OMIQ platform.

(Data sourced from selleck products)
In Vivo
In vivo

No effect of pemigatinib on the disease course is evident on acute EAE.[2]
Animal Research Animal Models Female C57Bl/6J mice of experimental autoimmune encephalomyelitis (EAE) model
Dosages 2.5 mg/kg
Administration i.n.

(Data sourced from selleck products)
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06302621 Recruiting
Advanced Solid Tumor|Unresectable Solid Tumor|Metastatic Solid Tumor|Cholangiocarcinoma
Massachusetts General Hospital|Boehringer Ingelheim|Incyte Corporation
 July 1 2024 Phase 1
NCT06389799 Not yet recruiting
Dedifferentiated Liposarcoma
Lund University Hospital
 May 7 2024 Phase 2
NCT05216120 Withdrawn
Pancreas Cancer
HonorHealth Research Institute|Incyte Corporation
 June 14 2022 Phase 2
NCT03914794 Recruiting
Bladder Cancer|NMIBC|Non-Muscle Invasive Bladder Cancer|Urothelial Carcinoma Recurrent
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Incyte Corporation
 October 2 2020 Phase 2
NCT04258527 Completed
Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.
 March 26 2020 Phase 1
NCT03235570 Completed
Solid Tumors
Incyte Corporation
 August 1 2017 Phase 1

Chemical Information & Solubility

Molecular Weight 487.50 Formula

C24H27F2N5O4
CAS No. 1513857-77-6 SDF --
Smiles CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

DMSO : 40 mg/mL ( (82.05 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Pemigatinib | Pemigatinib supplier | purchase Pemigatinib | Pemigatinib cost | Pemigatinib manufacturer | order Pemigatinib | Pemigatinib distributor